PMID- 36582607 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230103 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 13 DP - 2022 TI - Methylmalonic acid levels in serum, exosomes, and urine and its association with cblC type methylmalonic acidemia-induced cognitive impairment. PG - 1090958 LID - 10.3389/fneur.2022.1090958 [doi] LID - 1090958 AB - BACKGROUND: The cblC type methylmalonic acidemia is the most common methylmalonic acidemia (MMA) in China. The biochemical characteristics of this disease include elevated methylmalonic acid and homocysteine (HCY), increased propionylcarnitine (C3), decreased free carnitine (C0). In this study, we aimed to clarify the roles of these biomarkers in cblC-MMA induced cognitive impairment and evaluate the capacity of methylmalonic acid in different fluids or exosomes to distinguish cblC-MMA induced cognitive impairment. METHODS: 15 non-inherited hyperhomocysteinemia (HHcy) patients, 42 cblC-MMA patients and 57 age- and sex-matched healthy children were recruited in this study. The levels of HCY were detected by an automatic immune analyzer. The levels of acylcarnitines and methylmalonic acid were detected by tandem mass spectrometer. RESULTS: The main findings were all biomarkers as HCY, acylcarnitines and methylmalonic acid had capacities for distinguishing patients with cblC-MMA induced cognitive impairment from healthy children. The methylmalonic acid in different fluids or exosomes had good performances for distinguishing patients with cblC-MMA induced cognitive impairment from HHcy patients. The methylmalonic acid in serum exosomes and neuronal-derived exosomes were able to distinguishing cblC-MMA patients with cognitive impairment from patients without cognitive impairment. The methylmalonic acid in neuronal-derived exosomes might be helpful to evaluate the severity of cblC-MMA induced cognitive impairment. DISCUSSION: Methylmalonic acid levels in serum exosomes, especially in serum neuronal-derived exosomes, serve as potential biomarkers for distinguishing cblC-MMA induced cognitive impairment. CI - Copyright (c) 2022 Sun, Jin, Rong, Song and Li. FAU - Sun, Shuqi AU - Sun S AD - Department of Clinical Laboratory, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. FAU - Jin, Hong AU - Jin H AD - Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. FAU - Rong, Yu AU - Rong Y AD - Department of Rehabilitation, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. FAU - Song, Wenqi AU - Song W AD - Department of Clinical Laboratory, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. FAU - Li, Qiliang AU - Li Q AD - Department of Clinical Laboratory, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. LA - eng PT - Journal Article DEP - 20221213 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 PMC - PMC9792485 OTO - NOTNLM OT - cblC OT - cognitive impairment OT - exosomes OT - methylmalonic acid OT - methylmalonic acidemia COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/31 06:00 MHDA- 2022/12/31 06:01 PMCR- 2022/12/13 CRDT- 2022/12/30 02:26 PHST- 2022/11/06 00:00 [received] PHST- 2022/11/28 00:00 [accepted] PHST- 2022/12/30 02:26 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2022/12/31 06:01 [medline] PHST- 2022/12/13 00:00 [pmc-release] AID - 10.3389/fneur.2022.1090958 [doi] PST - epublish SO - Front Neurol. 2022 Dec 13;13:1090958. doi: 10.3389/fneur.2022.1090958. eCollection 2022.